EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis

Nigel Fleeman iD, Rachel Houten iD, Sarah Nevitt iD, James Mahon iD, Sophie Beale iD, Angela Boland iD, Janette Greenhalgh iD, Katherine Edwards iD, Michelle Maden iD, Devarshi Bhattacharyya iD, Marty Chaplin iD, Joanne McEntee iD und 2 weitere

Health Technology Assessment · 2024

DOI: 10.3310/trrm4238 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024. Verfasst von Nigel Fleeman und 13 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Cost-Benefit Analysis, Kidney Neoplasms. Die Arbeit nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal cell carcinoma is the most common type of kidney cancer, comprising approximately 85% of all renal malignancies. Patients with advanced renal cell carcinoma are the focus of this National Institute for Health and Care Excellence multiple technology appraisal. A patient’s risk of disease progression depends on a number of prognostic risk factors; patients are categorised as having intermediate/poor risk or favourable risk of disease progression.

Objectives

The objectives of this multiple technology appraisal were to appraise the clinical effectiveness and cost-effectiveness of lenvatinib plus pembrolizumab versus relevant comparators listed in the final scope issued by the National Institute for Health and Care Excellence: sunitinib, pazopanib, tivozanib, cabozantinib and nivolumab plus ipilimumab.

Methods

The assessment group carried out clinical and economic systematic reviews and assessed the clinical and cost-effectiveness evidence submitted by Eisai, Hatfield, Hertfordshire, UK (the manufacturer of lenvatinib) and Merck Sharp & Dohme, Whitehouse Station, NJ, USA (the manufacturer of pembrolizumab). The assessment group carried out fixed-effects network meta-analyses using a Bayesian framework to generate evidence for clinical effectiveness. As convergence issues occurred due to sparse data, random-effects network meta-analysis results were unusable. The assessment group did not develop a de novo economic model, but instead modified the partitioned survival model provided by Merck Sharp & Dohme.

Results

The assessment group clinical systematic review identified one relevant randomised controlled trial (CLEAR trial). The CLEAR trial is a good-quality, phase III, multicentre, open-label trial that provided evidence for the efficacy and safety of lenvatinib plus pembrolizumab compared with sunitinib. The assessment group progression-free survival network meta-analysis results for all three risk groups should not be used to infer any statistically significant difference (or lack of statistically significant difference) for any of the treatment comparisons owing to within-trial proportional hazards violations or uncertainty regarding the validity of the proportional hazards assumption. The assessment group overall survival network meta-analysis results for the intermediate-/poor-risk subgroup suggested that there was a numerical, but not statistically significant, improvement in the overall survival for patients treated with lenvatinib plus pembrolizumab compared with patients treated with cabozantinib or nivolumab plus ipilimumab. Because of within-trial proportional hazards violations or uncertainty regarding the validity of the proportional hazards assumption, the assessment group overall survival network meta-analysis results for the favourable-risk subgroup and the all-risk population should not be used to infer any statistically significant difference (or lack of statistically significant difference) for any of the treatment comparisons. Only one cost-effectiveness study was included in the assessment group review of cost-effectiveness evidence. The study was limited to the all-risk population, undertaken from the perspective of the US healthcare system and included comparators that are not recommended by the National Institute for Health and Care Excellence for patients with untreated advanced renal cell carcinoma. Therefore, the extent to which resource use and results are generalisable to the NHS is unclear. The assessment group cost-effectiveness results from the modified partitioned survival model focused on the intermediate-/poor-risk and favourable-risk subgroups. The assessment group cost-effectiveness results, generated using list prices for all drugs, showed that, for all comparisons in the favourable-risk subgroup, treatment with lenvatinib plus pembrolizumab costs more and generated fewer benefits than all other treatments available to NHS patients. For the intermediate-/poor-risk subgroup, treatment with lenvatinib plus pembrolizumab costs more and generated more benefits than treatment with cabozantinib and nivolumab plus ipilimumab.

Conclusions

Good-quality clinical effectiveness evidence for the comparison of lenvatinib plus pembrolizumab with sunitinib is available from the CLEAR trial. For most of the assessment group Bayesian hazard ratio network meta-analysis comparisons, it is difficult to reach conclusions due to within-trial proportional hazards violations or uncertainty regarding the validity of the proportional hazards assumption. However, the data (clinical effectiveness and cost-effectiveness) used to populate the economic model are relevant to NHS clinical practice and can be used to inform National Institute for Health and Care Excellence decision-making. The assessment group cost-effectiveness results, generated using list prices for all drugs, show that lenvatinib plus pembrolizumab is less cost-effective than all other treatment options. Study registration This study is registered as PROSPERO CRD4202128587. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR award ref: NIHR134985) and is published in full in Health Technology Assessment ; Vol. 28, No. 49. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Renal CellCost-Benefit AnalysisKidney NeoplasmsPhenylurea CompoundsQuinolinesHumansAntineoplastic Combined Chemotherapy ProtocolsCost-Effectiveness AnalysisQuality-Adjusted Life YearsRandomized Controlled Trials as TopicTechnology Assessment, Biomedical

Stichwörter der Autor:innen

COST-EFFECTIVENESS ANALYSISICERINDIRECT TREATMENT COMPARISONLENVATINIBPEMBROLIZUMABQALYRENAL CELL CARCINOMASYSTEMATIC REVIEW

Substanzen

Antibodies, Monoclonal, HumanizedlenvatinibpembrolizumabPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK.
  • Coldingham Analytical Services, Berwickshire, UK.
  • Hare Research, North Yorkshire, UK.
  • North West Medicines Information Centre, Liverpool, UK.
  • The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
  • The Christie NHS Foundation Trust, Manchester, UK.

ORCID-Profile: Nigel Fleeman, Rachel Houten, Sarah Nevitt, James Mahon, Sophie Beale, Angela Boland, Janette Greenhalgh, Katherine Edwards, Michelle Maden, Devarshi Bhattacharyya, Marty Chaplin, Joanne McEntee, Shien Chow, Tom Waddell

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Fleeman, N., Houten, R., Nevitt, S., Mahon, J., Beale, S., Boland, A., Greenhalgh, J., Edwards, K., Maden, M., Bhattacharyya, D., Chaplin, M., McEntee, J., Chow, S., & Waddell, T. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. https://doi.org/10.3310/trrm4238

Vancouver

Fleeman N, Houten R, Nevitt S, Mahon J, Beale S, Boland A, et al. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2024. doi:10.3310/trrm4238

BibTeX
@article{Fleeman2024,
  author = {Fleeman, Nigel and Houten, Rachel and Nevitt, Sarah and Mahon, James and Beale, Sophie and Boland, Angela and Greenhalgh, Janette and Edwards, Katherine and Maden, Michelle and Bhattacharyya, Devarshi and Chaplin, Marty and McEntee, Joanne and Chow, Shien and Waddell, Tom},
  title = {Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis},
  journal = {Health Technology Assessment},
  year = {2024},
  doi = {10.3310/trrm4238}
}
Kostenlos starten →